Literature DB >> 22377333

Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients.

Andreas M Stark1, Julia van de Bergh, Jürgen Hedderich, H Maximilian Mehdorn, Arya Nabavi.   

Abstract

OBJECTIVE: Glioblastoma is the most common and most malignant primary brain tumor in adults. The only overall accepted independent prognostic factors are patient age and performance. We present a large single institution patient series examined for prognostic factors using uni- and multivariate survival analysis.
METHODS: 492 patients were included who underwent craniotomy for newly diagnosed glioblastoma WHO grade IV between 1990 and 2007 at our department. The association to patient survival was estimated using log-rank test for univariate analysis and cox regression method for multivariate analysis.
RESULTS: Median patient age was 62 years (mean: 60.4 years, range: 22-93 years), the male: female ratio was 1.26:1. Primary genesis was found in 91.0% of cases. A multifocal tumor was present in 110 cases (22.4%). The median pre- and post-operative Karnofsky Performance Score was 70. Total tumor resection was performed in 288 cases (58.5%), subtotal removal in 134 cases (27.2%). The following parameters were significantly associated with survival in univariate analysis: age, performance, primary genesis, multifocal tumor, neurological deficit, neuropsychological findings, seizures, incidental finding, total or subtotal resection, radiotherapy, chemotherapy, combined radio-/chemotherapy with temozolomide, re-craniotomy, second tumor in patient history. The following parameters were significantly associated with survival in multivariate analysis: age, performance, multifocal tumor, total or subtotal resection, radiotherapy, chemotherapy, combined radio-/chemotherapy with temozolomide.
CONCLUSION: In addition to patient age and performance, we identified multiple lesions and resection status as independent prognostic factors. Radiotherapy, chemotherapy and combined radio-/chemotherapy with temozolomide were significantly associated with prolonged survival.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22377333     DOI: 10.1016/j.clineuro.2012.01.026

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  53 in total

1.  Prognostication of Survival Outcomes in Patients Diagnosed with Glioblastoma.

Authors:  Damir Nizamutdinov; Eileen M Stock; Jad A Dandashi; Eliana A Vasquez; Ying Mao; Samantha Dayawansa; Jun Zhang; Erxi Wu; Ekokobe Fonkem; Jason H Huang
Journal:  World Neurosurg       Date:  2017-09-23       Impact factor: 2.104

Review 2.  Treating glioblastoma patients with poor performance status: where do we go from here?

Authors:  Jaime Gállego Pérez-Larraya; François Ducray
Journal:  CNS Oncol       Date:  2014-05

3.  Benefit of tumor resection for recurrent glioblastoma.

Authors:  Johanna Quick; Florian Gessler; Stephan Dützmann; Elke Hattingen; Patrick N Harter; Lutz M Weise; Kea Franz; Volker Seifert; Christian Senft
Journal:  J Neurooncol       Date:  2014-02-15       Impact factor: 4.130

4.  Long non-coding RNA GASL1 may inhibit the proliferation of glioma cells by inactivating the TGF-β signaling pathway.

Authors:  Yuhua Hu; Baohua Jiao; Lingyou Chen; Man Wang; Xinwang Han
Journal:  Oncol Lett       Date:  2019-04-18       Impact factor: 2.967

5.  What is New in the Management of Epilepsy in Gliomas?

Authors:  Roberta Rudà; Riccardo Soffietti
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

6.  Early stage glioblastoma: retrospective multicentric analysis of clinical and radiological features.

Authors:  Isabella Ceravolo; Giovanni Barchetti; Francesco Biraschi; Carmela Gerace; Enrico Pampana; Alberto Pingi; Alessandro Stasolla
Journal:  Radiol Med       Date:  2021-08-02       Impact factor: 3.469

7.  Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.

Authors:  Francesca Nava; Irene Tramacere; Andrea Fittipaldo; Maria Grazia Bruzzone; Francesco Dimeco; Laura Fariselli; Gaetano Finocchiaro; Bianca Pollo; Andrea Salmaggi; Antonio Silvani; Mariangela Farinotti; Graziella Filippini
Journal:  Neuro Oncol       Date:  2014-01-23       Impact factor: 12.300

8.  The incidence and significance of multiple lesions in glioblastoma.

Authors:  Reena P Thomas; Linda W Xu; Robert M Lober; Gordon Li; Seema Nagpal
Journal:  J Neurooncol       Date:  2013-01-26       Impact factor: 4.130

9.  Innovative Hypofractionated Stereotactic Regimen Achieves Excellent Local Control with No Radiation Necrosis: Promising Results in the Management of Patients with Small Recurrent Inoperable GBM.

Authors:  Angela Jia; Susan C Pannullo; Shlomo Minkowitz; Shoshana Taube; Jenghwa Chang; Bhupesh Parashar; Paul Christos; A Gabriella Wernicke
Journal:  Cureus       Date:  2016-03-17

10.  Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis.

Authors:  Xingfu Wang; Yupeng Chen; Sheng Zhang; Lifeng Zhang; Xueyong Liu; Li Zhang; Xiaoling Li; Dayang Chen
Journal:  J Neurooncol       Date:  2015-09-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.